A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-650032 in subjects with chronic hepatitis C infection

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Asunaprevir

Criteria

Inclusion Criteria:

• Chronically infected with HCV genotype 1

• Treatment naive or treatment non-responders or treatment intolerant

• HCV RNA viral load of ≥10*5 IU/mL

• BMI 18 to 35kg/m²

Exclusion Criteria:

• Any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with HCV infection

• Major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug

• Co-infection with HIV or HBV

• Women of childbearing potential